For the year ending 2025-12-31, JSPRW had -$42,945K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total operating expense | 83,883 |
| Other income, net | 8,082 |
| Net loss | -75,801 |
| Depreciation and amortization expense | 1,056 |
| Impairment of long-lived assets | 1,112 |
| Non-cash lease expense | 1,164 |
| Stock-based compensation expense | 6,713 |
| Change in fair value of warrant liability | -8,528 |
| Offering costs recognized in other expense, net | 2,046 |
| Prepaid expenses and other current assets | 1,779 |
| Other non-current assets | -707 |
| Accounts payable | 2,193 |
| Accrued expenses and other current liabilities | -4,374 |
| Operating lease liability | -1,670 |
| Net cash used in operating activities | -77,161 |
| Purchases of property and equipment | 7 |
| Proceeds from sales of property and equipment | 12 |
| Net cash provided by (used in) investing activities | 5 |
| Proceeds from issuance of common stock through atm offering, net | 6,454 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net | 27,514 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 243 |
| Net cash provided by financing activities | 34,211 |
| Net decrease in cash, cash equivalents and restricted cash | -42,945 |
| Cash, cash equivalents and restricted cash at beginning of the year | 72,054 |
| Cash, cash equivalents and restricted cash at end of the year | 29,109 |
Jasper Therapeutics, Inc. (JSPRW)
Jasper Therapeutics, Inc. (JSPRW)